Contact information
Institute for Translational Epigenetics
University of Cologne
Weyertal 115b
50931 Cologne
CV
Academic education
| 1995 - 2002 | Biochemistry Studies, Free University Berlin and Leopold Franzens University Innsbruck |
| 1994 - 2001 | Medical School, Free University and Charité University Hospital Berlin |
Scientific degrees
| 04/2019 | Professor for Translational Epigenetics (W3), University Hospital Cologne |
| 01/2015 | Board examination in Human Genetics, Charité University Hospital Berlin |
| 01/2013 | Habilitation in Experimental Medicine, Charité University Hospital Berlin |
| 06/2008 | M.D., Medical School, Charité University Hospital Berlin (grade: Summa cum laude highest honors), supervisor: Prof. Dr. P.M. Howley, Department of Pathology, Harvard Medical School |
| 12/2005 | PhD, Biochemistry, Free University Berlin (grade: Summa cum laude highest honors), supervisor: Prof. Dr. P.M. Howley, Department of Pathology, Harvard Medical School |
| 10/2002 | Dipl. Biochem., Biochemistry, Free University Berlin |
| 11/2001 | Graduation from Medical School, Charité University Hospital Berlin |
Scientific career
| 2020/08 | Member of the selection committee for the Alexander von Humboldt foundation |
| 2019 - present | Lichtenberg professorship (W3), Institute for Translational Epigenetics, Medical Faculty University of Cologne |
| 2018/05 | Member of the selection committee Baden-Württemberg-Stiftung Epigenetik |
| 2019/01 - present | Elected Member of the selection committee ‘Science’ of the German Cancer Aid |
| 2015 - 2020 | Attending physician Human Genetics, University Hospital of Cologne |
| 2014 - 2019 | W2 Lichtenberg professorship, Functional Epigenomics, University of Cologne |
| 2007 - 2014 | Junior research group leader ‘Cancer genomics’, Max Planck Institute for Molecular Genetics Berlin |
| 2005 - 2007 | Postdoctoral research fellow, Harvard Medical School, Boston (Group of Professor Peter Howley, M.D.) |
| 2002 - 2005 | PhD student, Harvard Medical School, Boston (Group of Professor Peter Howley, M.D.) |
Honors/ Awards/ Memberships
| 2014 - present | W2/W3 Lichtenberg Professorship of the Volkswagen Stiftung |
| 2008 | Robert Koch Charité Dissertation Award |
| 2003 - 2005 | Fellowship from the "Studienstiftung des deutschen Volkes" |
| 1995 | 1st Place ‚Jugend Forscht‘ (region and land), special price environmental technology: ‚Hefe (Saccharomyces cerevisiae) – ein biologischer Monitor für Schutz und Schaden.’ |
Publications
-
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies
The BCL2 inhibitor venetoclax has been approved to treat different hematological malignancies. Because there is no common genetic alteration causing resistance to venetoclax in chronic lymphocytic leukemia (CLL) and B-cell lymphoma, we asked if epigenetic events might be involved in venetoclax…
-
Evaluation of a Prognostic Epigenetic Classification System in Chronic Lymphocytic Leukemia Patients
Methylation at 5 CpG sites was previously shown to classify chronic lymphocytic leukemia (CLL) into 3 prognostic subgroups. Here, we aimed to validate the marker set in an additional cohort and to evaluate its clinical utility for CLL patient stratification. We evaluated this epigenetic marker set…
-
Altered DNA Methylation Profiles in SF3B1 Mutated CLL Patients
Mutations in splicing factor genes have a severe impact on the survival of cancer patients. Splicing factor 3b subunit 1 (SF3B1) is one of the most frequently mutated genes in chronic lymphocytic leukemia (CLL); patients carrying these mutations have a poor prognosis. Since the splicing machinery…
-
Pericentromeric Satellite III transcripts induce etoposide resistance
Non-coding RNA from pericentromeric satellite repeats are involved in stress-dependent splicing processes, maintenance of heterochromatin, and are required to protect genome stability. Here we show that the long non-coding satellite III RNA (SatIII) generates resistance against the topoisomerase IIa…